Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Clinical trial NCT02954874 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02954874
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Carcinoma In Situ Invasive Breast Carcinoma Stage I Breast Cancer AJCC v7 Stage II Breast Cancer AJCC v6 and v7 Stage III Breast Cancer AJCC v7 Triple-Negative Breast Carcinoma

Start date: 2017-01-18
Primary completion: 2026-08-31
Enrollment: 1155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.